# PT 141: From Melanotan Research to an Approved Drug > PT 141 began as a melanocortin research compound and became bremelanotide, an FDA approved drug for low sexual desire in women. - URL: https://www.lifeconverted.com/learn/pt-141-research-overview - Category: Peptide Basics - Author: Hana Suzuki, Sleep & Cognition Writer - Published: 2026-09-16 - Updated: 2026-09-25 - Reading time: 3 min - Keywords: pt 141, bremelanotide, melanocortin 4 receptor, hypoactive sexual desire disorder --- PT 141 has an unusual resume for a peptide. It started life as a laboratory tool for studying skin pigmentation, got redirected toward sexual dysfunction research almost by accident, and eventually became an FDA approved drug under a completely different name. Most peptides you read about in research circles never reach that finish line. This one did, which makes it a useful case study in how a compound moves from bench to prescription pad, and where the two paths still diverge. ## Melanocortin background To understand PT 141, you need to start with melanocortins, a family of hormones and receptors that control far more than skin color. The melanocortin system includes five receptor types, MC1R through MC5R, spread across the skin, brain, adrenal glands, and immune cells. MC1R gets the most public attention because it governs pigmentation, which is why early melanocortin research focused on tanning agents. One of those early compounds was melanotan II, a synthetic analog of alpha melanocyte stimulating hormone built to activate multiple melanocortin receptors at once. Researchers testing melanotan II in the 1990s noticed something odd: volunteers reported spontaneous erections as a side effect. That observation shifted the entire research direction. If a melanocortin agonist could trigger arousal responses through the brain rather than the vascular system, it might work as a sexual dysfunction treatment through a different mechanism than existing drugs. Palatin Technologies picked up that thread and developed a more selective fragment of melanotan II, aimed specifically at the melanocortin 4 receptor, MC4R, which is heavily expressed in brain regions tied to sexual response. That fragment was given the lab name PT 141. Early pharmacology work described it plainly as a melanocortin agonist being developed for sexual dysfunction, distinct from the pigmentation focused compounds it descended from, as summarized in [Molinoff and colleagues' 2003 overview](https://pubmed.ncbi.nlm.nih.gov/12851303/). ## The approval story PT 141's first target was erectile dysfunction in men, a crowded field already dominated by PDE5 inhibitors like sildenafil. Early stage development explored that use, and a 2004 review of the compound's progress through Palatin's pipeline described intranasal PT 141 as a candidate with a different mechanism than existing ED drugs, working through the central nervous system rather than local blood flow, according to [Hedlund's 2004 summary](https://pubmed.ncbi.nlm.nih.gov/15134289/). That erectile dysfunction pathway eventually stalled. Attention shifted to female sexual dysfunction, specifically hypoactive sexual desire disorder, or HSDD, a diagnosis defined by persistent low sexual desire that causes distress and is not better explained by another medical or psychiatric condition. Clinical trial data compiled in the early 2010s supported this new direction, with subcutaneous injection studies showing measurable improvements in desire scores among women with HSDD, a body of evidence reviewed in [this 2012 analysis](https://pubmed.ncbi.nlm.nih.gov/34436837/). The compound, now called bremelanotide, went through the standard FDA review process under this narrower indication. It was approved in 2019 as Vyleesi, a self administered injection for acquired, generalized HSDD in premenopausal women. A 2019 drug profile in the journal *Drugs* documents this as the compound's first regulatory approval anywhere in the world, more than two decades after the original melanotan II observations, according to [Dhillon and colleagues](https://pubmed.ncbi.nlm.nih.gov/31429064/). It remains the only FDA approved use of this molecule. There is no approved form for men, and the erectile dysfunction indication that started the whole research program never reached market. HSDD itself is a well documented but historically undertreated condition. A 2021 review in the *Journal of Midwifery and Women's Health* lays out how the diagnosis is assessed and why treatment options had been limited for years before bremelanotide arrived, framing the drug's approval as filling a real gap in care rather than creating a new market from nothing, as described by [Pettigrew and colleagues](https://pubmed.ncbi.nlm.nih.gov/34510696/). ## How it works PT 141 and bremelanotide are the same molecule, so the mechanism is identical regardless of what you call it. It is a melanocortin receptor agonist, meaning it binds to and activates melanocortin receptors rather than blocking them. Its main target is MC4R, concentrated in brain regions involved in appetite, energy use, and sexual behavior. This is the detail that separates it from most other sexual dysfunction treatments. PDE5 inhibitors work locally, relaxing blood vessels to improve blood flow on demand. Bremelanotide works centrally, acting on brain pathways tied to desire itself rather than the mechanics of arousal. That is why it is dosed ahead of anticipated sexual activity rather than taken daily, and why its side effect profile looks different too, with nausea and flushing reported more often than the vascular side effects associated with PDE5 drugs. Because MC4R also plays a role in appetite regulation, some early interest in melanocortin agonists touched on metabolic effects as well, though PT 141 specifically was pursued for sexual dysfunction rather than weight related outcomes. If you want the fuller picture of how peptides bind receptors and trigger these kinds of downstream effects, the [complete guide to peptides](/learn/complete-guide-to-peptides) covers that mechanism in more general terms, and [how peptides work in the body](/learn/how-peptides-work-in-the-body) walks through receptor binding step by step. ## Research vs prescription forms Here is where things get confusing for anyone reading about PT 141 online. Vyleesi, the approved drug, is manufactured under pharmaceutical quality controls, dosed in a specific auto injector, and prescribed only for the HSDD indication after a clinical evaluation. It went through years of trial data review before the FDA signed off on it. PT 141 sold as a research chemical is a different product in every practical sense, even though the underlying peptide sequence is the same. Research grade vials are not manufactured under the same quality standards, are not dosed with any clinical guidance, and are not legally intended for human use. A 2026 review of therapeutic peptides in aesthetic and metabolic applications notes this exact tension across the peptide space: compounds with strong data and even regulatory approval in one form still circulate separately as unregulated research material, which creates real gaps in purity, labeling accuracy, and dosing consistency between the two markets, a pattern discussed by [Renke and colleagues](https://pubmed.ncbi.nlm.nih.gov/42123471/). This matters because the clinical trial evidence behind bremelanotide, including the desire score improvements documented in earlier trial work such as [this 2006 study](https://pubmed.ncbi.nlm.nih.gov/31369224/), applies to the tested, regulated formulation and dosing schedule. It does not automatically transfer to material purchased from a research supplier with no chain of custody or quality verification. Anyone comparing the two should treat them as separate products with separate evidence bases, not interchangeable versions of the same drug. If you are trying to track which peptides have reached approved status, which are still purely investigational, and how a given compound's research history lines up with any approved use, the [LifeConverted peptide reference library](/all-peptides) organizes that information by compound so you are not piecing it together from scattered sources. ## Common questions **Is PT 141 the same thing as bremelanotide?** Yes. PT 141 is the research name for the compound that became the approved drug bremelanotide, sold under the brand name Vyleesi. **What is PT 141 approved for?** Bremelanotide is FDA approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. No form of the compound is approved for men. **Why is PT 141 still sold as a research chemical if a drug exists?** Vials labeled PT 141 for research use are not the regulated, quality controlled product sold as Vyleesi, and they are not approved for human use. *This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.* ## FAQ ### Is PT 141 the same thing as bremelanotide? Yes. PT 141 is the research name for the compound that became the approved drug bremelanotide, sold under the brand name Vyleesi. ### What is PT 141 approved for? Bremelanotide is FDA approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. No form of the compound is approved for men. ### Why is PT 141 still sold as a research chemical if a drug exists? Vials labeled PT 141 for research use are not the regulated, quality controlled product sold as Vyleesi, and they are not approved for human use. ## Sources - Hedlund P, 2004, Curr Opin Investig Drugs: https://pubmed.ncbi.nlm.nih.gov/15134289/ - Molinoff PB et al., 2003, Ann N Y Acad Sci: https://pubmed.ncbi.nlm.nih.gov/12851303/ - Dhillon S et al., 2019, Drugs: https://pubmed.ncbi.nlm.nih.gov/31429064/ - Pettigrew JA et al., 2021, J Midwifery Womens Health: https://pubmed.ncbi.nlm.nih.gov/34510696/ - 2012: https://pubmed.ncbi.nlm.nih.gov/34436837/ --- Published by LifeConverted, https://www.lifeconverted.com/learn/pt-141-research-overview